Fluoguide AS
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical T… Read more
Fluoguide AS (FLUO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 4.485x
Based on the latest financial reports, Fluoguide AS (FLUO) has a cash flow conversion efficiency ratio of 4.485x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.97 Million) by net assets (Skr-2.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Fluoguide AS - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Fluoguide AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Fluoguide AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fluoguide AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Madison Pacific Properties Inc.
TO:MPC
|
0.008x |
|
Eyenovia Inc
NASDAQ:EYEN
|
0.457x |
|
Hengyuan Refining Company Bhd
KLSE:4324
|
0.281x |
|
TRANSCONTL RLTY INV.DL-01
F:TI9
|
N/A |
|
Future Health Esg Corp
NASDAQ:FHLT
|
0.653x |
|
RSUPPORT Co. Ltd
KQ:131370
|
0.000x |
|
Exasol AG
XETRA:EXL
|
1.256x |
|
Tait Marketing & Distribution Co Ltd
TWO:5902
|
0.046x |
Annual Cash Flow Conversion Efficiency for Fluoguide AS (2018–2024)
The table below shows the annual cash flow conversion efficiency of Fluoguide AS from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr23.07 Million | Skr-29.15 Million | -1.264x | +49.46% |
| 2023-12-31 | Skr12.72 Million | Skr-31.81 Million | -2.501x | -112.36% |
| 2022-12-31 | Skr31.97 Million | Skr-37.65 Million | -1.178x | -202.57% |
| 2021-12-31 | Skr38.70 Million | Skr-15.06 Million | -0.389x | +80.60% |
| 2020-12-31 | Skr4.41 Million | Skr-8.85 Million | -2.006x | +13.68% |
| 2019-12-31 | Skr4.54 Million | Skr-10.55 Million | -2.323x | -1390.74% |
| 2018-12-31 | Skr7.00K | Skr-1.09K | -0.156x | -- |